CTRI/2022/10/046524
Not yet recruiting
Phase 3
A CLINICAL STUDY TO FIND OUT THE CHANGES INPULMONARY FUNCTION TEST IN ALLERGIC BRONCHIALASTHMA WITH INDIVIDUALISED HOMOEOPATHIC MEDICINE
Dr GEETHU K P0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dr GEETHU K P
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patient with age 18\- 60 years of any gender.
- •2\. Patients with reduction in FEV1 / FVC Ratio ( below 70 %)
- •3\. Patient with increased serum IgE level.
- •4\. Patient with signs and symptoms of allergic asthma.
Exclusion Criteria
- •1\. Patients with immune deficiency diseases like AIDS, cancer etc
- •2\. Patients with systemic illness that is contraindicated in spirometry (myocardial
- •infarction, pneumothorax , large aneurysm etc).
- •3\. Status asthmaticus
- •4\. Pregnant and lactating mother
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
on-invasive assessment of lung remodeling in patients with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) using [11C]-Nintedanib or [18F]-FLT PET imaging.NL-OMON44254Vrije Universiteit90
Completed
Not Applicable
ew pulmonary function assessment using chest X-ray dynamic digital radiographyChronic obstructive pulmonary disease (COPD), In terstitial lung disease (ILD)JPRN-jRCTs042220018Ohkura Noriyuki160
Recruiting
Not Applicable
Breath analysis of the patients with few missing teeth after the placement of removable artificial teeth setHealth Condition 1: K084- Partial loss of teethCTRI/2024/07/071718Dr.Prudhvi Rudraraju
Withdrawn
Not Applicable
Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress SyndromeRespiratory Distress SyndromeNCT01537354University of Michigan
Recruiting
Not Applicable
A study to evaluate the long-term effect of pulmonary hypertension on prognosis, activities of daily living (ADL), cardiac function and pulmonary function in patients with COPD and IPF, respectively, according to baseline severity of pulmonary hypertension and the efficacy and safety of the Tracleer (bosentan hydrate) tablet for prognosis, activities of daily living, cardiac function and pulmonary function in patients with COPD and IIPs, respectively, according to baseline severity of pulmonary hypertension.Patients with COPD or IPF (WHO functional class II, III or IV), without hypoxia (PaO2 at rest<90mmHg or after 6minutes walk), who provide their informed consent to participate in this study.JPRN-UMIN000004749Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School160